NZ575093A - Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma - Google Patents

Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma

Info

Publication number
NZ575093A
NZ575093A NZ575093A NZ57509307A NZ575093A NZ 575093 A NZ575093 A NZ 575093A NZ 575093 A NZ575093 A NZ 575093A NZ 57509307 A NZ57509307 A NZ 57509307A NZ 575093 A NZ575093 A NZ 575093A
Authority
NZ
New Zealand
Prior art keywords
antibody
fragment
seq
afra
heavy chain
Prior art date
Application number
NZ575093A
Other languages
English (en)
Inventor
Franck Martin
Margherita Cattozzo
Giovanni Maurizi
Cioccio Vito Di
Mariangela Figini
Silvana Canevari
Original Assignee
Dompe Pha R Ma Spa Res & Mfg
Ist Naz Stud Cura Dei Tumori
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe Pha R Ma Spa Res & Mfg, Ist Naz Stud Cura Dei Tumori filed Critical Dompe Pha R Ma Spa Res & Mfg
Publication of NZ575093A publication Critical patent/NZ575093A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NZ575093A 2006-09-15 2007-09-12 Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma NZ575093A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06019399A EP1900752A1 (en) 2006-09-15 2006-09-15 Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma
PCT/EP2007/007944 WO2008031577A1 (en) 2006-09-15 2007-09-12 Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma

Publications (1)

Publication Number Publication Date
NZ575093A true NZ575093A (en) 2012-04-27

Family

ID=37737768

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ575093A NZ575093A (en) 2006-09-15 2007-09-12 Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma

Country Status (14)

Country Link
US (1) US8388972B2 (enExample)
EP (2) EP1900752A1 (enExample)
JP (1) JP5513114B2 (enExample)
KR (1) KR101497045B1 (enExample)
AU (1) AU2007296899B2 (enExample)
BR (1) BRPI0716811B8 (enExample)
CA (1) CA2662005C (enExample)
ES (1) ES2644423T3 (enExample)
IL (1) IL197300A (enExample)
MX (1) MX2009002711A (enExample)
NZ (1) NZ575093A (enExample)
RU (1) RU2464277C2 (enExample)
WO (1) WO2008031577A1 (enExample)
ZA (1) ZA200901328B (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005214331B2 (en) 2004-02-12 2011-09-15 Eisai, Inc. Monoclonal antibodies that specifically bind to folate receptor alpha
AU2006241099B2 (en) 2005-04-22 2012-04-19 Eisai, Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
SG10201501342UA (en) * 2010-02-24 2015-04-29 Immunogen Inc Folate receptor 1 antibodies and immunoconjugates and uses thereof
EP2614084A4 (en) 2010-09-09 2014-02-19 Purdue Research Foundation HUMANE FOLAT RECEPTOR BETA ANTIBODIES AND METHOD FOR THEIR USE
SG189957A1 (en) * 2010-11-05 2013-06-28 Morphotek Inc Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers
AU2012207356A1 (en) 2011-01-18 2013-08-01 The Trustees Of The University Of Pennsylvania Compositions and methods for treating cancer
US20140010756A1 (en) 2011-03-18 2014-01-09 Kagoshima University Composition for treatment and diagnosis of pancreatic cancer
SI2694106T1 (en) * 2011-04-01 2018-04-30 Immunogen, Inc. Methods for increasing the effectiveness of treatment with FOLR1 receptor cancer
SI2731972T1 (en) 2011-07-15 2018-04-30 Eisai R&D Management Co., Ltd. Anti-folate receptor alpha antibodies and uses thereof
WO2013026839A1 (en) * 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
US9629918B2 (en) 2012-02-29 2017-04-25 Purdue Research Foundation Folate receptor alpha binding ligands
US9200073B2 (en) * 2012-08-31 2015-12-01 Immunogen, Inc. Diagnostic assays and kits for detection of folate receptor 1
WO2014055771A1 (en) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Human alpha-folate receptor chimeric antigen receptor
US20150320799A1 (en) 2012-12-20 2015-11-12 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
CA3222465A1 (en) 2013-08-30 2015-03-05 Immunogen, Inc. Antibodies and assays for detection of folate receptor 1
PT3055332T (pt) * 2013-10-08 2019-12-09 Immunogen Inc Regimes de dosagem de imunoconjugados anti-folr1
KR101646577B1 (ko) * 2014-08-14 2016-08-09 원광대학교산학협력단 엽산수용체 표적용 화합물 또는 이의 약학적으로 허용가능한 염과, 이를 유효성분으로 포함하는 암 예방, 진단 또는 치료용 조성물
CN107074955B (zh) 2014-11-20 2021-06-22 豪夫迈·罗氏有限公司 针对FolR1和CD3的T细胞活化性双特异性抗原结合分子
LT3789402T (lt) 2014-11-20 2022-09-26 F. Hoffmann-La Roche Ag Kompleksinė terapija, naudojant t ląsteles aktyvinančias bispecifines antigeną surišančias molekules ir pd-1 ašį surišančius antagonistus
RS60615B1 (sr) 2014-11-20 2020-08-31 Hoffmann La Roche Zajednički laki lanci i postupci upotrebe
CN116440279A (zh) 2015-09-17 2023-07-18 伊缪诺金公司 包含抗folr1免疫缀合物的治疗组合
JP7282521B2 (ja) 2016-04-08 2023-05-29 パーデュー・リサーチ・ファウンデイション Ｃａｒ ｔ細胞療法のための方法および組成物
EP3496757A4 (en) 2016-08-12 2020-04-15 L.E.A.F Holdings Group LLC POLYGLUTAMATE ANTIFOLATES AND USES THEREOF.
WO2018031980A1 (en) 2016-08-12 2018-02-15 L.E.A.F. Holdings Group Llc Polyglutamated antifolates and uses thereof
CN110944651A (zh) 2017-02-08 2020-03-31 蜻蜓疗法股份有限公司 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途
ES2955074T3 (es) 2017-02-20 2023-11-28 Dragonfly Therapeutics Inc Proteínas que se unen a HER2, NKG2D Y CD16
WO2018160622A1 (en) 2017-02-28 2018-09-07 Endocyte, Inc. Compositions and methods for car t cell therapy
WO2019094648A1 (en) 2017-11-08 2019-05-16 L.E.A.F. Holdings Group Llc Platinum complexes and uses thereof
AU2019209432A1 (en) 2018-01-22 2020-08-06 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods of use for CAR T cells
CA3090236A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
SG11202007482WA (en) 2018-02-08 2020-09-29 Dragonfly Therapeutics Inc Antibody variable domains targeting the nkg2d receptor
KR102832460B1 (ko) 2018-02-20 2025-07-11 드래곤플라이 쎄라퓨틱스, 인크. Cd33, nkg2d, 및 cd16에 결합하는 다중-특이적 결합 단백질, 및 이의 사용 방법
WO2019165237A1 (en) 2018-02-23 2019-08-29 Endocyte, Inc. Sequencing method for car t cell therapy
CN115925952A (zh) 2018-03-13 2023-04-07 东莞凡恩世生物医药有限公司 抗叶酸受体1抗体及其用途
MX2021001527A (es) 2018-08-08 2021-06-15 Dragonfly Therapeutics Inc Proteínas de unión a nkg2d, cd16 y a un antígeno asociado a tumor.
MA53293A (fr) 2018-08-08 2021-11-17 Dragonfly Therapeutics Inc Protéines de liaison multi-spécifiques se liant à bcma, nkg2d et cd16, et méthodes d'utilisation
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
KR20220004687A (ko) 2019-04-29 2022-01-11 이뮤노젠 아이엔씨 이중파라토프 fr-알파 항체 및 면역접합체
CA3149914A1 (en) 2019-08-06 2021-02-11 L.E.A.F. Holdings Group Llc Processes of preparing polyglutamated antifolates and uses of their compositions
CN111393528B (zh) * 2020-01-19 2023-01-31 中国药科大学 一种靶向叶酸受体α的单链抗体及其应用
MX2022013944A (es) 2020-05-06 2022-11-30 Dragonfly Therapeutics Inc Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a).
WO2022187539A1 (en) 2021-03-03 2022-09-09 Dragonfly Therapeutics, Inc. Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen
CN117700557B (zh) * 2024-02-05 2024-04-30 卡秋(江苏)生物科技有限公司 一种特异性结合叶酸受体α的抗体或抗原结合片段
CN119757601A (zh) * 2025-01-06 2025-04-04 哈尔滨脉图精准技术有限公司 一种用于卵巢癌诊断的代谢标志物组合及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003074679A2 (en) * 2002-03-01 2003-09-12 Xencor Antibody optimization
DK1517921T3 (da) * 2002-06-28 2006-10-09 Domantis Ltd Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
AU2005214331B2 (en) 2004-02-12 2011-09-15 Eisai, Inc. Monoclonal antibodies that specifically bind to folate receptor alpha
KR101461408B1 (ko) * 2005-10-06 2014-11-13 어드밴스드 엑셀러레이터 어플리케이션즈 에스.에이. 신규 선택 시스템

Also Published As

Publication number Publication date
WO2008031577A1 (en) 2008-03-20
CA2662005A1 (en) 2008-03-20
IL197300A0 (en) 2011-08-01
BRPI0716811B1 (pt) 2020-11-24
ES2644423T3 (es) 2017-11-28
JP2010503386A (ja) 2010-02-04
US8388972B2 (en) 2013-03-05
EP1900752A1 (en) 2008-03-19
IL197300A (en) 2016-02-29
KR20090059114A (ko) 2009-06-10
CA2662005C (en) 2018-01-02
KR101497045B1 (ko) 2015-02-27
RU2009114161A (ru) 2010-10-20
BRPI0716811A2 (pt) 2013-11-05
AU2007296899B2 (en) 2012-09-13
AU2007296899A1 (en) 2008-03-20
BRPI0716811B8 (pt) 2021-05-25
MX2009002711A (es) 2009-06-18
JP5513114B2 (ja) 2014-06-04
EP2061813B1 (en) 2017-07-19
EP2061813A1 (en) 2009-05-27
RU2464277C2 (ru) 2012-10-20
US20100055034A1 (en) 2010-03-04
WO2008031577A8 (en) 2009-07-02
ZA200901328B (en) 2010-05-26

Similar Documents

Publication Publication Date Title
AU2007296899B2 (en) Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma
JP6077745B2 (ja) 抗ポドプラニン抗体、及び抗ポドプラニン抗体を含む医薬組成物
AU2017288985B2 (en) Anti-MET antibodies and uses thereof
CN106188305A (zh) 具有融合至常规Fab片段的单域抗原结合片段的二价抗体
US20170158755A1 (en) Anti-laminin4 antibodies specific for lg1-3
WO2022166876A1 (zh) 特异性识别磷脂酰肌醇蛋白聚糖3的单克隆抗体及其应用
US20250011427A1 (en) Anti-cd3 antibodies with cross-reactivity to human and cynomolgus proteins
CA3203257A1 (en) Anti-b7-h3 antibody and uses thereof
KR20250042144A (ko) Itga2를 표적으로 하는 항체 및 이를 포함하는 항체-약물 접합체(antibody targeting itga2 and antibody-drug conjugate comprising the same)
US20240417469A1 (en) Cd3-targeting t-cell engagers with improved therapeutic index
JP2025520692A (ja) 抗ｓｌｃ３４ａ２モノクローナル抗体およびその使用
US10584175B2 (en) FN14-binding proteins and uses thereof
US20240026004A1 (en) ANTI-PD-L1/TGF-ß BIFUNCTIONAL ANTIBODY AND USE THEREOF
WO2025131054A1 (en) Antibody drug conjugates targeting to b7-h3 and egfr and the use thereof
WO2025195495A1 (zh) 一种放射性核素偶联物及其制备方法和用途
KR20250174736A (ko) L1cam을 표적화하는 항체 및 이의 용도
KR20250069411A (ko) 항 ceacam5 항체 및 이의 용도
TW202539735A (zh) 一種包含特異性結合ｄｌｌ３和ｃｄ３的雙特異性抗體的醫藥組成物
CN120025446A (zh) 结合分子及抗体药物偶联物和用途
TW202442681A (zh) 抗ror1抗體及其藥物偶聯物
CN117402255A (zh) 抗人pd-l1和人ox40的双特异抗体及其应用
BR112018005837B1 (pt) Anticorpo anti-mesotelina, ácido nucleico, vetor, célula hospedeira, método de preparação do anticorpo e composição farmacêutica

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 12 SEP 2017 BY CPA GLOBAL

Effective date: 20140731

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 SEP 2018 BY CPA GLOBAL

Effective date: 20170727

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 SEP 2019 BY ACUMASS

Effective date: 20180817

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 SEP 2020 BY ACUMASS

Effective date: 20190819

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 SEP 2021 BY ACUMASS

Effective date: 20200819

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 SEP 2022 BY ACUMASS

Effective date: 20210823

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 SEP 2023 BY OLIVIER BARLOY

Effective date: 20220811

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 SEP 2024 BY CPA GLOBAL

Effective date: 20230817

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 SEP 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20240822

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 SEP 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20250821